Meeting
2023 ASCO Annual Meeting
Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.
Authors
Michael Dickinson
The Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Vic, VIC, Australia
Michael Dickinson , Andreas Viardot , Reinhard Marks , Max S. Topp , Franck Morschhauser , Benedikt Jacobs , Monica Tani , Francesc Bosch , Daniel Esteban , Raul Cordoba , Derrick Kaufman , Chun Wu , Kathryn Humphrey , Pauline Baumlin , Martin Barrett , Naseer Qayum , Antonio Pinto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03467373
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7549)
DOI
10.1200/JCO.2023.41.16_suppl.7549
Abstract #
7549
Poster Bd #
100
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
First Author: Bei Hu
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
First Author: Carrie Ho
Poster
2020 ASCO Virtual Scientific Program
REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL).
First Author: Manfred Welslau
Poster
2023 ASCO Annual Meeting
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).
First Author: David Lavie